Valuation: AbbVie Inc.

Market Cap 521B 17,604B 467B 429B 389B 727B 49,479B 741B 5,119B 2,055B 26,028B 1,956B 1,914B 82,081B P/E 2026 *
36.7x
P/E 2027 * 28x
Enterprise Value 583B 19,694B 522B 480B 435B 813B 55,352B 829B 5,727B 2,299B 29,117B 2,188B 2,141B 91,824B EV / Sales 2026 *
8.6x
EV / Sales 2027 * 7.8x
Free-Float
95.71%
Yield 2026 *
2.35%
Yield 2027 * 2.46%
1 day+3.06%
1 week+5.21%
1 month+14.12%
3 months+17.44%
6 months+53.03%
Current year+38.36%
1 week 9.55
Extreme 9.55
10.1
1 month 8.7
Extreme 8.7
10.1
Current year 6.25
Extreme 6.25
10.1
1 year 6.25
Extreme 6.25
10.1
3 years 6.25
Extreme 6.25
10.1
5 years 6.25
Extreme 6.25
10.1
10 years 6.25
Extreme 6.25
10.1
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Chief Tech/Sci/R&D Officer - 29/02/2024
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 69 31/12/2012
Change 5-day change 1-year change 3-year change Capi.($)
+3.06%+5.21% - - 521B
+3.19%+11.31%+64.28%+155.66% 1,263B
-0.73%+3.56%+44.65%+83.74% 658B
+1.41%+3.24%+35.25%+106.98% 521B
+0.42%+3.20%+55.81%+69.71% 391B
+2.18%+2.93%+73.90%+45.38% 369B
+1.12%+4.52%+34.76%+57.00% 307B
+6.96%+8.86%+11.95%+35.06% 290B
+1.15%+6.09%+56.15%+78.66% 252B
+3.06%+9.38%+42.48%+112.84% 212B
Average +2.18%+5.90%+46.58%+82.78% 473.55B
Weighted average by Cap. +2.12%+6.60%+50.51%+99.19%

Financials

2026 *2027 *
Net sales 67.77B 2,290B 60.7B 55.83B 50.59B 94.56B 6,435B 96.33B 666B 267B 3,385B 254B 249B 10,675B 73.76B 2,492B 66.06B 60.77B 55.06B 103B 7,004B 105B 725B 291B 3,684B 277B 271B 11,618B
Net income 15.98B 540B 14.31B 13.16B 11.93B 22.29B 1,517B 22.71B 157B 63.01B 798B 59.97B 58.69B 2,517B 19.08B 644B 17.08B 15.72B 14.24B 26.62B 1,811B 27.11B 187B 75.23B 953B 71.59B 70.07B 3,005B
Net Debt 61.85B 2,089B 55.39B 50.95B 46.17B 86.3B 5,873B 87.91B 608B 244B 3,089B 232B 227B 9,742B 54.18B 1,830B 48.52B 44.63B 40.44B 75.59B 5,144B 77.01B 532B 214B 2,706B 203B 199B 8,534B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
30/10/26 THB 10.10 +3.06% 32,066
29/10/26 THB 9.800 +1.03% 11,185
28/10/26 THB 9.700 +0.52% 982
27/10/26 THB 9.650 -0.52% 638
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
294.89USD
Average target price
297.15USD
Spread / Average Target
+0.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.